Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CaPre in Hypertriglyceridemia
NCT01516151Phase 2Completed
- Sponsor
- Grace Therapeutics, Inc.
- Start
- Dec 2011
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CaPre in hypertriglyceridemia (5 arms), sponsored by Grace Therapeutics, Inc. Primary endpoint: Percent change in fasting blood circulating serum TGs at 4 weeks. Started Dec 2011; status: completed.
02
Drugs
CaPre
03
Conditions
hypertriglyceridemia
Beyond the preview
Go deeper on NCT01516151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01516151.